Cancer Immunotherapy Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Cancer immunotherapy represents one of the fastest-growing segments within the global oncology therapeutics market, addressing a wide range of solid and hematologic malignancies through immune-system modulation. The market stands at approximately $150.25 billion in 2025 and is forecast to reach $162 billion in 2026, reinforcing an aggressive double-digit expansion trajectory. Underlying growth reflects a maturing pipeline of approved therapies, broader insurance coverage, and increased clinician familiarity with immune-related adverse event management.

• •Market size in 2025: ~$150.25 billion, with a forecast $162 billion in 2026
• •Long-term projections point to $247 billion by 2029 and up to $366.28 billion by 2035
• •Historical baseline: approximately $128.74 billion in 2023

Rising global cancer prevalence and earlier diagnosis are expanding the addressable patient pool, while a steady flow of regulatory approvals for novel immune-based drugs is widening treatment options. Pharmaceutical companies are increasingly pairing immunotherapies with chemotherapy, targeted agents, and radiotherapy to improve response rates and durability, which is driving per-patient spending. Reimbursement reforms in major markets and rising healthcare investment in emerging economies are further accelerating adoption.

• •Expanding approvals of checkpoint inhibitors and cell-based therapies across multiple tumor types
• •Combination regimens (immuno-oncology plus targeted therapy or chemotherapy) lifting effectiveness and revenue per patient
• •Improved reimbursement frameworks and rising oncology infrastructure in Asia-Pacific

By therapy type, the market is typically segmented into monoclonal antibodies (the largest share, anchored by checkpoint inhibitors), immunomodulators, cancer vaccines, adoptive cell therapies (including CAR-T), and oncolytic viral therapies. By indication, non-small cell lung cancer, melanoma, breast cancer, leukemia, lymphoma, and renal cell carcinoma account for the majority of revenue. North America leads global sales due to high treatment costs and rapid uptake of newly approved biologics, while Asia-Pacific is the fastest-growing region as China, Japan, and India expand access.

• •Monoclonal antibodies remain the dominant therapy class, led by anti-PD-1/PD-L1 and anti-CTLA-4 agents
• •Solid tumors (lung, melanoma, breast, renal) drive most volume; hematologic cancers anchor cell-therapy demand
• •North America holds the largest revenue share; Asia-Pacific is the fastest-growing region

What are the recent trends and outlook?

Near-term momentum is being driven by label expansions of approved checkpoint inhibitors into earlier lines of therapy and adjuvant settings, which significantly enlarges the treatable population. Cell therapies are moving beyond hematologic cancers into solid tumors, supported by advances in manufacturing automation and improved efficacy data. Looking out to 2035, the category is expected to more than double, propelled by AI-enabled target discovery, biomarker-driven patient selection, and broader deployment in community oncology settings.

• •Shift toward earlier-line and adjuvant use of checkpoint inhibitors is expanding patient populations
• •CAR-T and next-generation cell therapies are pushing into solid-tumor indications
• •AI-driven target identification, biomarker-guided treatment selection, and decentralized manufacturing are key to sustaining 11.4% CAGR through the decade